Human Anti-CD117 / c-Kit Antibody Product Attributes
CD117 / c-Kit Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-KIT antibody staining is expected to be primarily localized to the plasma membrane. There is variability in either the signal strength or the localization of signal in plasma membrane from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in CD117 / c-Kit antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of CD117 / c-Kit could be seen inepidermal cells in the skin. We were unable to detect CD117 / c-Kit in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD117 / c-Kit expression as measured by anti-CD117 / c-Kit antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
KIT Variability | + | ++ | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | ++ | ++ | + |
CD117 / c-Kit General Information | |
---|---|
Alternate Names | |
cKit, CD117, c-KIT, Stem cell growth factor receptor, SCFR | |
Molecular Weight | |
~145kDa | |
Chromosomal Location | |
4q12 | |
Curated Database and Bioinformatic Data | |
Gene Symbol | KIT |
Entrez Gene ID | 3815 |
Ensemble Gene ID | ENSG00000157404 |
RefSeq Protein Accession(s) | XP_005265799, XP_016863668, XP_016863669, NP_001087241, XP_005265798, XP_016863667, XP_005265797, NP_000213 |
RefSeq mRNA Accession(s) | XM_005265742, XM_017008179, XM_005265741, XM_017008178, XM_005265740, NM_001093772, NM_000222 |
RefSeq Genomic Accession(s) | NC_018915, NG_007456, NC_000004 |
UniProt ID(s) | P10721, A0A0U2N547, A0A024RDA0 |
UniGene ID(s) | P10721, A0A0U2N547, A0A024RDA0 |
HGNC ID(s) | 6342 |
Cosmic ID(s) | KIT |
KEGG Gene ID(s) | hsa:3815 |
PharmGKB ID(s) | PA30128 |
General Description of CD117 / c-Kit. | |
This MAb recognizes a protein of 145kDa, identified as CD117/p145kit. It is found on a wide variety of tumor cells including follicular, papillary carcinoma of thyroid, adenocarcinomas from endometrium, lung, ovary, pancreas,, breast as well as malignant melanoma, endodermal sinus tumor,, small cell carcinoma. However, anti-CD117 has been particularly useful in differentiating gastrointestinal stromal tumors from Kaposis sarcoma, tumors of smooth muscle origin, fibromatosis,, neural tumors of the GI tract. Anti-CD117 is also useful in recognizing myeloblasts in bone marrow biopsy, clot section. |
There are no reviews yet.